Results 41 to 50 of about 29,165 (230)

Some considerations on the WHO Histological classification of laryngeal neoplasms [PDF]

, 2019
A new edition of the World Health Organization (WHO) Histological classification of tumours of the hypopharynx, larynx, trachea and parapharyngeal space was published in 2017.
Devaney, Kenneth O., Ferlito, Alfio, Hellquist, Henrik, Hunt, Jennifer L.   +3 more
core   +2 more sources

GI Synovial Sarcomas

Clinical and Translational Gastroenterology, 2012
Synovial sarcoma accounts for about 10% of adult soft tissue sarcomas, with 80–90% located in the limbs. Gastrointestinal tract involvement is rare. Synovial sarcoma has a propensity for local recurrence and lung metastases, which can be delayed beyond 5 years.
Sinniah, Rajeev Palar, Roche, Enrico, Cameron, Donald   +2 more
openaire   +2 more sources

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis. [PDF]

, 2016
Synovial sarcomas are aggressive soft-tissue malignancies that express chromosomal translocation-generated fusion genes, SS18-SSX1 or SS18-SSX2 in most cases.
Barrott, JJ, Cairns, BR, Capecchi, MR, Ding, L, Haldar, M, Jin, H, Jones, KB, Langer, EM, Monument, MJ, Mosbruger, TL, Randall, RL, Wilson, RK, Xie, M, Zhu, J-F   +13 more
core  

Sarcoma immunotherapy. [PDF]

, 2011
Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential ...
Gouw, Launce G, Jones, Kevin B, Randall, R Lor, Sharma, Sunil   +3 more
core   +2 more sources

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Salvage resection of advanced mediastinal tumors [PDF]

, 2019
The surgical treatment of locally advanced mediastinal tumors invading the great vessels and other nearby structures still represent a tricky question, principally due to the technical complexity of the resective phase, the contingent need to carry out
Andreetti, Claudio, Ciccone, Anna Maria, D’Andrilli, Antonio, Ibrahim, Mohsen, Maurizi, Giulio, Menna, Cecilia, Poggi, Camilla, Rendina, Erino Angelo, Vanni, Camilla, Venuta, Federico   +9 more
core   +1 more source

Nerve growth factor is sufficient to cause multiple osteoarthritis‐relevant pathological features in naïve murine knee joints

Arthritis &Rheumatology, Accepted Article.
Objective Nerve growth factor (NGF), a key mediator of pain, is increased in osteoarthritic (OA) joints. Antibodies against NGF show analgesic effects in painful knee OA, but clinical development was stopped due to side‐effects in the joints. Knowledge about the biological effects of NGF on joint tissues is limited.
Alia M. Obeidat, Michael D. Newton, Jun Li, Baofeng Hu, Shingo Ishihara, Lindsey Lammlin, Lucas M. Junginger, Easton C. Farrell, Lai Wang, Frank C. Ko, Richard J. Miller, Carla R. Scanzello, Tristan Maerz, Rachel E. Miller, Anne‐Marie Malfait   +14 more
wiley   +1 more source

Truncated SSX Protein Suppresses Synovial Sarcoma Cell Proliferation by Inhibiting the Localization of SS18-SSX Fusion Protein [PDF]

, 2013
Synovial sarcoma is a relatively rare high-grade soft tissue sarcoma that often develops in the limbs of young people and induces the lung and the lymph node metastasis resulting in poor prognosis.
Ito, Sachio, Kanzaki, Hirotaka, Kunisada, Toshiyuki, Morimoto, Yuki, Ouchida, Mamoru, Ozaki, Toshifumi, Shimizu, Kenji, Yoneda, Yasushi, Yoshida, Aki   +8 more
core   +3 more sources

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source